| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2726593 | Seminars in Radiation Oncology | 2015 | 9 Pages |
Abstract
Following combined-modality therapy for the treatment of low-grade gliomas, the assessment of treatment response and the evaluation of disease progression are uniformly challenging. In this article, we review existing response criteria, and discuss the limitations of conventional magnetic resonance imaging to distinguish between progression and treatment effect. We review the data on advanced imaging techniques including positron emission tomography and functional magnetic resonance imaging, which may enhance the interpretation of posttreatment changes, and enable the earlier assessment of the efficacy and toxicity of therapy in these patients with prolonged survival.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Michelle M. Kim, Theodore S. Lawrence, Yue Cao,